PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL BioPharma Responds to Class Action Lawsuit
PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors
PDL BioPharma Completes Regular Quarterly Dividend Payment
PDL BioPharma Provides Third Quarter 2014 Revenue Guidance of $165 Million
PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes